Protalix BioTherapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	15.33	-6.6	2.93	8.31	-14.93	-27.58
Depreciation & Amortization	1.52	1.47	1.3	1.19	1.09	1.12
Stock-Based Compensation	2.29	2.3	3.25	3.45	2.09	2.38
Other Adjustments	1.67	0.95	0.37	-3.73	-1.23	3.9
Change in Receivables	2.79	-5.89	2.32	-0.43	-1.19	-1.03
Changes in Inventories	-10.97	-4.49	-2.2	-2.24	1.15	-4.87
Changes in Accounts Payable	2.4	0.29	0.7	5.3	-4.8	2.39
Changes in Unearned Revenue	-	-	-	-13.18	-7.16	13.23
Changes in Other Operating Activities	0.06	-0.02	-0	0.01	-0.01	0.19
Operating Cash Flow	15.09	-11.99	8.67	-1.32	-25	-10.29
Capital Expenditures	-2.09	-1.64	-1.28	-1.15	-0.63	-1.46
Sale of Property, Plant & Equipment	-	-	0	-	-	0.05
Purchases of Investments	-5	-5	-15	-20.42	-16	-37.84
Proceeds from Sale of Investments	15	5	20.42	5	11	57.84
Other Investing Activities	-0.03	-0.73	0.08	-0.14	0.59	0.33
Investing Cash Flow	2.17	-2.37	4.22	-16.71	-5.04	18.92
Long-Term Debt Repaid	-	-	-20.42	-	-	-34.12
Net Long-Term Debt Issued (Repaid)	-	-	-20.42	-	-	-34.12
Issuance of Common Stock	4.4	9.33	3.63	24.67	8.24	46.2
Net Common Stock Issued (Repurchased)	4.4	9.33	3.63	24.67	8.24	46.2
Financing Cash Flow	4.4	9.33	-16.79	24.67	8.24	12.08
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.12	-0.05	0.03	-0.11	-0.08	0.01
Net Cash Flow	21.54	-5.08	-3.87	6.52	-21.87	20.72
Free Cash Flow	13	-13.63	7.39	-2.47	-25.63	-11.74
FCF Margin	17.02%	-25.84%	13.84%	-3.77%	-53.80%	-30.62%
Free Cash Flow Per Share	0.16	-0.17	0.09	-0.03	-0.53	-0.27
Levered Free Cash Flow	6.25	-10.99	-18.97	-1.76	-25.29	-51.11
Unlevered Free Cash Flow	8.71	-8.91	3.59	0.7	-22.9	-9.87

SEC Filings: 10-K · 10-Q